JW Pharmaceutical Corporation (KRX:001060)

South Korea flag South Korea · Delayed Price · Currency is KRW
25,750
-600 (-2.28%)
Last updated: Jun 30, 2026, 2:02 PM KST
Market Cap586.25B +9.9%
Revenue (ttm)789.95B +9.1%
Net Income68.83B +14.6%
EPS3,103.24 +21.7%
Shares Out 22.89M
PE Ratio8.28
Forward PEn/a
Dividend650.00 (2.52%)
Ex-Dividend DateMar 31, 2026
Volume23,846
Open26,300
Previous Close26,350
Day's Range25,600 - 26,500
52-Week Range20,700 - 39,250
Beta0.95
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About JW Pharmaceutical

JW Pharmaceutical Corporation manufactures and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cancer, immunological disease, cardiovascular system and metabolic diseases, regenerative medicine, eye diseases , and pancreatic cancer. The company also offers infant care system, gynecological examining table, operating room equipment, steam sterilizer, and other equipment. In addition, it offers wound care, pain care, and beauty care related products. The company was founded in 1945 and is base... [Read more]

Sector Healthcare
Founded 1945
Employees 1,068
Stock Exchange Korea Stock Exchange
Ticker Symbol 001060
Full Company Profile

Financial Performance

In 2025, JW Pharmaceutical's revenue was 775.30 billion, an increase of 7.77% compared to the previous year's 719.38 billion. Earnings were 60.65 billion, a decrease of -6.75%.

Financial Statements

News

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

BEIJING and BRIDGEWATER, N.J. , April 9, 2026 /CNW/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement with JW...

2 months ago - Benzinga